Related Experiment Videos
Pimecrolimus in dermatology: atopic dermatitis and beyond
Paolo Gisondi1, Charles N Ellis, Giampiero Girolomoni
1Department of Dermatology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy.
International Journal of Clinical Practice
|July 22, 2005
Summary
Pimecrolimus, a topical calcineurin inhibitor, effectively treats inflammatory skin conditions like atopic dermatitis (AD) with minimal systemic absorption and side effects. It offers a safe alternative to corticosteroids, showing efficacy in various dermatoses.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Pimecrolimus is a topical calcineurin inhibitor for inflammatory skin diseases, notably atopic dermatitis (AD).
- It selectively targets T cells and mast cells, inhibiting key inflammatory mediators.
- Unlike other treatments, it avoids effects on dendritic cells, endothelial cells, and fibroblasts, preventing skin atrophy.
Purpose of the Study:
- To evaluate the efficacy and safety of topical pimecrolimus in treating inflammatory skin conditions.
- To compare pimecrolimus's mechanism of action and side effect profile with other treatments like tacrolimus and corticosteroids.
Main Methods:
- Review of randomized controlled trials (RCTs) assessing topical pimecrolimus cream 1% (Elidel).
- Analysis of pimecrolimus's effects on T cells, mast cells, and other skin cells.
- Assessment of systemic absorption and side effect profiles.
Main Results:
- Topical pimecrolimus cream 1% demonstrated effectiveness, good tolerability, and safety in adults and children with mild to moderate AD.
- Pimecrolimus inhibits T-cell proliferation and inflammatory cytokine release (IL-2, IL-4, IFN-γ, TNF-α) and mast cell degranulation.
- Low skin penetration results in minimal systemic exposure and side effects, unlike corticosteroids.
Conclusions:
- Topical pimecrolimus is an effective and safe treatment option for mild to moderate atopic dermatitis in various age groups.
- Its targeted mechanism and favorable safety profile make it suitable for inflammatory skin diseases beyond AD, including seborrheic dermatitis and psoriasis.